{"id":56832,"date":"2026-02-11T00:23:22","date_gmt":"2026-02-10T16:23:22","guid":{"rendered":"https:\/\/flcube.com\/?p=56832"},"modified":"2026-02-11T00:23:23","modified_gmt":"2026-02-10T16:23:23","slug":"sanofis-wayrilz-wins-fda-breakthrough-and-japan-orphan-designation-for-rare-blood-disorder","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=56832","title":{"rendered":"Sanofi\u2019s Wayrilz Wins FDA Breakthrough and Japan Orphan Designation for Rare Blood Disorder"},"content":{"rendered":"\n

Sanofi<\/strong> (NASDAQ:\u202fSNY<\/a><\/strong>) announced that the U.S. Food and Drug Administration (FDA)<\/strong> has granted Breakthrough Therapy Designation (BTD)<\/strong> to Wayrilz (rilzabrutinib)<\/strong> for warm autoimmune hemolytic anemia (wAIHA)<\/strong>, while the Japanese Ministry of Health, Labour and Welfare<\/strong> has simultaneously awarded Orphan Drug Designation (ODD)<\/strong> for the same indication. The novel oral reversible BTK inhibitor<\/strong>, already approved for immune thrombocytopenia (ITP)<\/strong> in the US, EU, and UAE, now advances toward first-in-class therapy<\/strong> for a rare anemia with no disease-targeting treatments currently available<\/strong>.<\/p>\n\n\n\n

Regulatory Milestone<\/h2>\n\n\n\n
Item<\/th>Detail<\/th><\/tr><\/thead>
Company<\/strong><\/td>Sanofi (NASDAQ:\u202fSNY)<\/td><\/tr>
Asset<\/strong><\/td>Wayrilz (rilzabrutinib) \u2013 Oral reversible BTK inhibitor<\/td><\/tr>
FDA Designation<\/strong><\/td>Breakthrough Therapy Designation (BTD)<\/strong> \u2013 wAIHA<\/td><\/tr>
Japan Designation<\/strong><\/td>Orphan Drug Designation (ODD)<\/strong> \u2013 wAIHA (MHLW)<\/td><\/tr>
Approved Indications<\/strong><\/td>Immune thrombocytopenia (ITP) \u2013 US, EU, UAE<\/td><\/tr>
Under Review<\/strong><\/td>ITP \u2013 Japan<\/td><\/tr>
Clinical Basis<\/strong><\/td>LUMINA 2 (Phase 2b, NCT05002777) and LUMINA 3 (Phase 3, NCT07086976)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Target Disease & Unmet Need<\/h2>\n\n\n\n
Parameter<\/th>wAIHA Profile<\/th>Strategic Significance<\/th><\/tr><\/thead>
Disease Mechanism<\/strong><\/td>Autoimmune destruction of red blood cells (warm IgG-mediated)<\/td>B-cell driven pathology; BTK inhibition addresses root cause<\/td><\/tr>
Clinical Burden<\/strong><\/td>Anemia, fatigue, jaundice; risk of thrombosis and organ damage<\/td>High morbidity; current treatments (steroids, rituximab) non-specific<\/td><\/tr>
Treatment Gap<\/strong><\/td>No approved therapy targeting underlying cause<\/strong><\/td>First disease-modifying opportunity in wAIHA<\/td><\/tr>
Prevalence<\/strong><\/td>Rare disease (~1-3 per 100,000) \u2013 qualifies for orphan incentives<\/td>Premium pricing; accelerated regulatory pathways<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Rilzabrutinib Differentiation & Clinical Data<\/h2>\n\n\n\n
Feature<\/th>Wayrilz Profile<\/th>Competitive Advantage<\/th><\/tr><\/thead>
Mechanism<\/strong><\/td>Oral, reversible BTK inhibitor<\/strong><\/td>Avoids irreversible BTK inhibitor toxicities (atrial fibrillation, bleeding)<\/td><\/tr>
Administration<\/strong><\/td>Once or twice daily oral<\/td>Patient convenience vs. IV rituximab or chronic steroids<\/td><\/tr>
Selectivity<\/strong><\/td>Reversible binding allows physiologic BTK function recovery<\/td>Improved safety profile for chronic autoimmune use<\/td><\/tr>
Clinical Evidence<\/strong><\/td>LUMINA 2\/3 studies demonstrating efficacy in wAIHA<\/td>BTD\/ODD validation of meaningful benefit over available therapies<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Strategic Positioning & Market Context<\/h2>\n\n\n\n
Factor<\/th>Strategic Value<\/th><\/tr><\/thead>
BTK Class Expansion<\/strong><\/td>Wayrilz extends Sanofi’s BTK franchise<\/strong> beyond ITP into autoimmune hemolytic anemia<\/strong>, creating hematology autoimmune platform<\/strong><\/td><\/tr>
Rare Disease Premium<\/strong><\/td>wAIHA orphan designation enables pricing power<\/strong> and regulatory exclusivity<\/strong> in US, EU, and Japan<\/td><\/tr>
Reversible BTK Differentiation<\/strong><\/td>Positioned as best-in-class safety<\/strong> vs. irreversible competitors (ibrutinib, acalabrutinib) in autoimmune settings requiring chronic dosing<\/td><\/tr>
LUMINA Program Validation<\/strong><\/td>Dual Phase 2b\/3 studies supporting designations demonstrate robust clinical investment<\/strong> and high confidence in efficacy signal<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Development Roadmap<\/h2>\n\n\n\n
Phase<\/th>Activity<\/th>Timeline<\/th><\/tr><\/thead>
Current<\/strong><\/td>LUMINA 2 (Phase 2b) and LUMINA 3 (Phase 3) ongoing; BTD\/ODD accelerate development<\/td>2026<\/td><\/tr>
Regulatory<\/strong><\/td>FDA rolling review initiation; Japan JNDA submission for wAIHA<\/td>2026-2027<\/td><\/tr>
Approval<\/strong><\/td>Potential US and Japan wAIHA approvals<\/td>2027-2028<\/td><\/tr>
Expansion<\/strong><\/td>Additional autoimmune hemolytic indications (cold agglutinin disease)<\/td>Post-approval<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Forward\u2011Looking Statements<\/strong>
This brief contains forward\u2011looking statements regarding rilzabrutinib regulatory approval timelines in wAIHA, commercial potential in rare autoimmune anemia, and Sanofi’s BTK platform expansion. Actual results may differ due to LUMINA 3 Phase 3 trial outcomes, competitive dynamics with FcRn inhibitors (efgartigimod) and complement blockers, and rare disease commercial execution challenges.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Sanofi (NASDAQ:\u202fSNY) announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[34,867,24,147],"class_list":["post-56832","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-breakthrough-therapy","tag-nasdaq-sny","tag-rare-orphan-disease-drugs","tag-sanofi"],"yoast_head":"\nSanofi\u2019s Wayrilz Wins FDA Breakthrough and Japan Orphan Designation for Rare Blood Disorder - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Sanofi (NASDAQ:\u202fSNY) announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to Wayrilz (rilzabrutinib) for warm autoimmune hemolytic anemia (wAIHA), while the Japanese Ministry of Health, Labour and Welfare has simultaneously awarded Orphan Drug Designation (ODD) for the same indication. The novel oral reversible BTK inhibitor, already approved for immune thrombocytopenia (ITP) in the US, EU, and UAE, now advances toward first-in-class therapy for a rare anemia with no disease-targeting treatments currently available.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=56832\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Sanofi\u2019s Wayrilz Wins FDA Breakthrough and Japan Orphan Designation for Rare Blood Disorder\" \/>\n<meta property=\"og:description\" content=\"Sanofi (NASDAQ:\u202fSNY) announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to Wayrilz (rilzabrutinib) for warm autoimmune hemolytic anemia (wAIHA), while the Japanese Ministry of Health, Labour and Welfare has simultaneously awarded Orphan Drug Designation (ODD) for the same indication. The novel oral reversible BTK inhibitor, already approved for immune thrombocytopenia (ITP) in the US, EU, and UAE, now advances toward first-in-class therapy for a rare anemia with no disease-targeting treatments currently available.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=56832\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-10T16:23:22+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-02-10T16:23:23+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56832#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56832\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Sanofi\u2019s Wayrilz Wins FDA Breakthrough and Japan Orphan Designation for Rare Blood Disorder\",\"datePublished\":\"2026-02-10T16:23:22+00:00\",\"dateModified\":\"2026-02-10T16:23:23+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56832\"},\"wordCount\":472,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Breakthrough therapy\",\"NASDAQ: SNY\",\"Rare \\\/ orphan disease drugs\",\"Sanofi\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=56832#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56832\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=56832\",\"name\":\"Sanofi\u2019s Wayrilz Wins FDA Breakthrough and Japan Orphan Designation for Rare Blood Disorder - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-02-10T16:23:22+00:00\",\"dateModified\":\"2026-02-10T16:23:23+00:00\",\"description\":\"Sanofi (NASDAQ:\u202fSNY) announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to Wayrilz (rilzabrutinib) for warm autoimmune hemolytic anemia (wAIHA), while the Japanese Ministry of Health, Labour and Welfare has simultaneously awarded Orphan Drug Designation (ODD) for the same indication. The novel oral reversible BTK inhibitor, already approved for immune thrombocytopenia (ITP) in the US, EU, and UAE, now advances toward first-in-class therapy for a rare anemia with no disease-targeting treatments currently available.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56832#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=56832\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56832#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Sanofi\u2019s Wayrilz Wins FDA Breakthrough and Japan Orphan Designation for Rare Blood Disorder\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Sanofi\u2019s Wayrilz Wins FDA Breakthrough and Japan Orphan Designation for Rare Blood Disorder - Insight, China's Pharmaceutical Industry","description":"Sanofi (NASDAQ:\u202fSNY) announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to Wayrilz (rilzabrutinib) for warm autoimmune hemolytic anemia (wAIHA), while the Japanese Ministry of Health, Labour and Welfare has simultaneously awarded Orphan Drug Designation (ODD) for the same indication. The novel oral reversible BTK inhibitor, already approved for immune thrombocytopenia (ITP) in the US, EU, and UAE, now advances toward first-in-class therapy for a rare anemia with no disease-targeting treatments currently available.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=56832","og_locale":"en_US","og_type":"article","og_title":"Sanofi\u2019s Wayrilz Wins FDA Breakthrough and Japan Orphan Designation for Rare Blood Disorder","og_description":"Sanofi (NASDAQ:\u202fSNY) announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to Wayrilz (rilzabrutinib) for warm autoimmune hemolytic anemia (wAIHA), while the Japanese Ministry of Health, Labour and Welfare has simultaneously awarded Orphan Drug Designation (ODD) for the same indication. The novel oral reversible BTK inhibitor, already approved for immune thrombocytopenia (ITP) in the US, EU, and UAE, now advances toward first-in-class therapy for a rare anemia with no disease-targeting treatments currently available.","og_url":"https:\/\/flcube.com\/?p=56832","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-02-10T16:23:22+00:00","article_modified_time":"2026-02-10T16:23:23+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=56832#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=56832"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Sanofi\u2019s Wayrilz Wins FDA Breakthrough and Japan Orphan Designation for Rare Blood Disorder","datePublished":"2026-02-10T16:23:22+00:00","dateModified":"2026-02-10T16:23:23+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=56832"},"wordCount":472,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Breakthrough therapy","NASDAQ: SNY","Rare \/ orphan disease drugs","Sanofi"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=56832#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=56832","url":"https:\/\/flcube.com\/?p=56832","name":"Sanofi\u2019s Wayrilz Wins FDA Breakthrough and Japan Orphan Designation for Rare Blood Disorder - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-02-10T16:23:22+00:00","dateModified":"2026-02-10T16:23:23+00:00","description":"Sanofi (NASDAQ:\u202fSNY) announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to Wayrilz (rilzabrutinib) for warm autoimmune hemolytic anemia (wAIHA), while the Japanese Ministry of Health, Labour and Welfare has simultaneously awarded Orphan Drug Designation (ODD) for the same indication. The novel oral reversible BTK inhibitor, already approved for immune thrombocytopenia (ITP) in the US, EU, and UAE, now advances toward first-in-class therapy for a rare anemia with no disease-targeting treatments currently available.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=56832#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=56832"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=56832#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Sanofi\u2019s Wayrilz Wins FDA Breakthrough and Japan Orphan Designation for Rare Blood Disorder"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/56832","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=56832"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/56832\/revisions"}],"predecessor-version":[{"id":56833,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/56832\/revisions\/56833"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=56832"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=56832"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=56832"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}